Biogen Idec Inc. said yesterday that it has formed a consortium with several academic research centers that looks to identify new approaches to treating amyotrophic lateral sclerosis, or ALS, which is also known as Lou Gehrig’s disease. Spyros Artavanis-Tsakonas, HMS professor of cell biology, is also the company’s senior vice president and chief scientific officer.
